KR20020084876A - Composition comprising an extract of malva verticillata l. for hormone replacement theraphy - Google Patents
Composition comprising an extract of malva verticillata l. for hormone replacement theraphy Download PDFInfo
- Publication number
- KR20020084876A KR20020084876A KR1020010024276A KR20010024276A KR20020084876A KR 20020084876 A KR20020084876 A KR 20020084876A KR 1020010024276 A KR1020010024276 A KR 1020010024276A KR 20010024276 A KR20010024276 A KR 20010024276A KR 20020084876 A KR20020084876 A KR 20020084876A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- estrogen
- hormone replacement
- composition
- hormone
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 229940088597 hormone Drugs 0.000 title claims description 12
- 239000005556 hormone Substances 0.000 title claims description 12
- 240000003065 Malva verticillata Species 0.000 title abstract description 6
- 235000002384 Malva verticillata Nutrition 0.000 title abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 28
- 235000013402 health food Nutrition 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940011871 estrogen Drugs 0.000 claims description 25
- 239000000262 estrogen Substances 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- 229960004592 isopropanol Drugs 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 230000001076 estrogenic effect Effects 0.000 abstract description 11
- 238000002657 hormone replacement therapy Methods 0.000 abstract description 9
- 230000027455 binding Effects 0.000 abstract description 8
- 230000003054 hormonal effect Effects 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract description 2
- 238000007911 parenteral administration Methods 0.000 abstract description 2
- 206010002261 Androgen deficiency Diseases 0.000 abstract 1
- 101000626071 Homo sapiens Deoxynucleotidyltransferase terminal-interacting protein 2 Proteins 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 102000055649 human DNTTIP2 Human genes 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 13
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 9
- 239000000583 progesterone congener Substances 0.000 description 9
- 208000001132 Osteoporosis Diseases 0.000 description 7
- 102000015694 estrogen receptors Human genes 0.000 description 7
- 108010038795 estrogen receptors Proteins 0.000 description 7
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 229910052802 copper Inorganic materials 0.000 description 6
- 239000010949 copper Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- 239000000469 ethanolic extract Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 206010014733 Endometrial cancer Diseases 0.000 description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000009245 menopause Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 2
- KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000033830 Hot Flashes Diseases 0.000 description 2
- 206010060800 Hot flush Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000000982 Malva neglecta Species 0.000 description 2
- 235000000060 Malva neglecta Nutrition 0.000 description 2
- 206010030247 Oestrogen deficiency Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 238000009164 estrogen replacement therapy Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 description 1
- 206010010214 Compression fracture Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000219071 Malvaceae Species 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010033165 Ovarian failure Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000098700 Sarcocheilichthys parvus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- SCGJLFGXXZTXSX-UHFFFAOYSA-N copper;ethanol Chemical compound [Cu].CCO SCGJLFGXXZTXSX-UHFFFAOYSA-N 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- -1 ethyl oleate Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000539 ovarian failure Toxicity 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 206010041569 spinal fracture Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 동규자 (Malva verticillata L.) 추출물을 유효성분으로 하는 호르몬 대체 치료용 조성물에 관한 것으로, 구체적으로 동규자로부터 물 또는 저급알콜을 이용하여 분리·정제되고 인간 에스트로젠 수용체 (human estrogen receptor)에 대한 결합활성을 나타내는 동규자 추출물을 유효성분으로 하는 조성물에 관한 것이다.The present invention relates to a composition for treating hormone replacement using an extract of Malva verticillata L. as an active ingredient, specifically, it is isolated and purified from water using a low alcohol or a human estrogen receptor. The present invention relates to a composition comprising a copper sperm extract exhibiting binding activity as an active ingredient.
미국 내에서만 4000,0000명 이상의 여성이 매년 폐경기에 접어든다. 마지막 월경기에 도달한 여성의 평균 연령은 약 28세이고, 이중 약 75 ~ 85%는 에스트로젠 결핍증으로 발전할 것이라고 1982년 한 연구에서 지적하였다 (Hammond et al.,Fertil. Steril., 37(1):5-25, 1982). 난소부전의 시작에 따르는 가장 일반적인 질환의 하나는 '핫 플래쉬 (hot flash)' 또는 혈관운동 증 (症) 콤플랙스로서 이는 돌연히 시작되어 일반적으로 수분간 지속되는 온기, 빈번하게 관찰되는 붉은 플래쉬 및 종종 현기증, 구역질, 두통, 심계항진 및 발한을 동반하는데, 적당한 에스트로젠을 공급함으로써 이러한 증상들의 90% 이상을 경감할 수 있다.In the United States alone, more than 4000 million women enter menopause each year. The average age of women who reached the last menstrual age was about 28 years, of which about 75 to 85 percent would develop estrogen deficiency (Hammond et al., Fertil. Steril. , 37 (1)). : 5-25, 1982). One of the most common diseases following the onset of ovarian failure is 'hot flash' or vasomotor complexes, which are suddenly occurring and generally last for several minutes, frequently observed red flashes and often Accompanying dizziness, nausea, headache, palpitations, and sweating, more than 90% of these symptoms can be alleviated by providing adequate estrogen.
만성적인 저 (低) 에스트로젠에 의한 후폐경기 증상이 많이 있으며, 이중 가장 심각한 것은 골다공증과 허혈성(虛熱性) 심장질환이다. 60세 이상의 여성 중 25%는 에스트로젠 결핍에 관련된 골다공증의 결과로서 척추압박골절을, 50%는 75세에척추골절로 발전된 것이 보고되었다. 고령에서 둔부골절의 비율이 매우 높은 것 역시 이러한 골다공증에 기인하는 것이다.There are many postmenopausal symptoms caused by chronic low estrogen, the most serious of which are osteoporosis and ischemic heart disease. It has been reported that 25% of women older than 60 years have developed vertebral compression fractures as a result of osteoporosis associated with estrogen deficiency, and 50% have developed vertebral fractures at age 75. The very high rate of hip fractures in old age is also attributable to this osteoporosis.
에스트로겐 또는 에스트로겐/게스타겐 배합물로의 호르몬 대체 치료 (hormone replacement therapy, HRT)는 현재 폐경기와 관련된 증상을 치료하기 위한 표준 방법으로 알려져 왔다 (Ernster, V. L. et al.,Prev. Med., 17:201-223, 1988).Hormone replacement therapy (HRT) with estrogens or estrogen / gestagen combinations is now known as the standard method for treating symptoms associated with menopause (Ernster, VL et al., Prev. Med ., 17: 201-223, 1988).
에스트로겐은 심장혈관계, 골 (골다공증의 위험의 감소) 및 중추 신경계 (핫 플래쉬의 회피)에 대해 보호작용을 한다. 그러나, 호르몬 대체 치료에서 에스트로겐의 만성적인 사용은 자궁내막암의 위험을 증가시킨다 (Ernster, V. L. et al.,Prev. Med., 17:201-223, 1988). 이러한 위험을 감소시키기 위하여 게스타겐을 동시에 사용함으로써 자궁내막에 대한 에스트로겐의 자극 효과가 억제되지만 (Gibbson, W. E.,Am. J. Obstet. Gynecol., 154: 46-61, 1986), 반대로 에스트로겐 및 게스타겐의 배합 치료의 경우 혈장 지질에 대한 에스트로겐 성분의 보호 효과가 악화되는 문제점이 지적되고 있다 (Lobo, R. Am.J. Obstet. Gynecol., 166: 1997-2004, 1992).Estrogens protect the cardiovascular system, bone (reduced risk of osteoporosis) and central nervous system (avoid hot flashes). However, chronic use of estrogen in hormone replacement therapy increases the risk of endometrial cancer (Ernster, VL et al., Prev. Med ., 17: 201-223, 1988). Simultaneous use of gestagen to reduce this risk inhibits the stimulating effect of estrogen on the endometrium (Gibbson, WE, Am. J. Obstet. Gynecol. , 154: 46-61, 1986), but in contrast, estrogen and In the case of the combination treatment of gestagens , there is a problem of deteriorating the protective effect of the estrogen component on plasma lipids (Lobo, R. Am. J. Obstet. Gynecol ., 166: 1997-2004, 1992).
게다가, 경구용 피임약을 사용하는 것 보다 낮은 호르몬 투여량을 기준으로 한 에스트로겐/게스타겐으로, 바람직하지 않은 주기내 월경 출혈이 일어날 수 있다 (Hillard , T. C. et al.,Am. J. Obstet. Gynecol., 167: 1-7, 1992). 마지막으로, 최근 논문은 많은 게스타겐이 유방암의 위험을 증가시킬 수 있다는 것을 보여준다 (Staffa, J. A. et al.,An Epidemiologic Review, 57: 473-491, 1992; King, R. J. B.,J. Ster. Biochem. Molec. Bio., 39: 8111-8118, 1991).Moreover, with estrogen / gestagen based on lower hormonal dosages than using oral contraceptives, undesirable intra-menstrual bleeding can occur (Hillard, TC et al., Am. J. Obstet. Gynecol. , 167: 1-7, 1992). Finally, recent papers show that many gestagens may increase the risk of breast cancer (Staffa, JA et al., An Epidemiologic Review , 57: 473-491, 1992; King, RJB, J. Ster. Biochem Molec. Bio ., 39: 8111-8118, 1991).
특히, 에스트로젠 대체 치료는 자궁이 있는 여성에게 더 복잡한 이슈이다. 에스트로젠 치료는 연속적인 '경쟁이 없는' 에스트로젠에 의해 유도된 자궁내막의 증식 때문에 자궁내막암의 발생 빈도 증가와 관련된다. 규칙적인 프로제스틴의 투여는 반증식 효과를 통하여 자궁내막의 연속적인 에스트로젠 자극을 억제하여, 몇 개의 주름에 의해 에스트로젠을 받는 폐경기 여성에 있어서 자궁내막암의 비율을 감소시키는 것으로 보인다 (Barbieri et al.,Menopause Management, 7/8월, 12-24, 1992). 그러나, 에스트로젠과 프로제스틴의 조합은 바람직하지 않은 자궁출혈을 빈번하게 일으키며 프로제스틴에 의해 에스트로젠의 심혈관 효과가 최소화될 수있는 단점이 있다. 그럼에도 불구하고, 일련의 동시 발생적인 프로제스틴을 더한 에스트로젠의 섭생은 현재 자궁이 있는 폐경기 여성에게 호르몬 대체 치료의 일반적인 형태로 사용된다.In particular, estrogen replacement therapy is a more complex issue for women with the uterus. Estrogen treatment is associated with an increased incidence of endometrial cancer due to proliferation of the endometrium induced by continuous 'competitive' estrogens. Regular administration of progestin seems to reduce the rate of endometrial cancer in postmenopausal women who receive estrogen by several folds through the antiproliferative effect (Barbieri et al., Menopause Management , July / August, 12-24, 1992). However, the combination of estrogen and progestin frequently causes undesirable uterine bleeding and has the disadvantage that the cardiovascular effect of estrogen can be minimized by progestin. Nevertheless, estrogen's regimen, plus a series of concurrent progestins, is now used as a common form of hormone replacement therapy in postmenopausal women.
또한, 에스트로젠은 치매 치료에 효과적인 것으로 보고되었으며 (Black SE, Patterson C., Feightner J.,Can. J. Neurol. Sci.,Feb:28 Suppl 1:S56-66, 2001), 신경 보호 작용 (Dubal DB., Wise PM.,Endocrinology,Jan;142(1):43-8, 2001) 및 퇴행성 신경 질환에 대한 개선효과 (Kim H., Xia H., Li L., Gewin J.,Biofactors,12(1-4):243-50, 2000)를 나타낸다고 보고된 바 있다.In addition, estrogens have been reported to be effective in treating dementia (Black SE, Patterson C., Feightner J., Can. J. Neurol. Sci., Feb: 28 Suppl 1: S56-66, 2001), neuroprotective action (Dubal DB., Wise PM., Endocrinology, Jan; 142 (1): 43-8, 2001) and improvement effects on neurodegenerative diseases (Kim H., Xia H., Li L., Gewin J., Biofactors, 12 (1-4): 243-50, 2000).
한편, 동규자는 아욱과 (Malvaceae)에 속하는 아욱 (Malva verticillata Linne)의 종자로서, 아욱은 습기 있는 밭에서 자라는 높이 60 ∼ 90 cm 정도의 식물이다. 아욱의 줄기는 곧게 서며 긴 성모 (星毛:여러 갈래로 갈라진 별 모양의 털)가 나있고, 잎은 어긋나고 둥글며 5 ∼ 7갈래로 얕게 갈라지고 가장자리에 뭉툭한 톱니가 있다. 꽃은 6 ∼ 7월에 연분홍색으로 피는데 잎겨드랑이에 모여 달리며, 재래 채소로서 연한 식물체를 국거리로 이용한다. 한방에서 종자를 동규자 (冬葵子) 또는 규자라 하여 분비나 배설을 원활하게 하는 약재로 사용한다. 동규자는 통변 (通便), 통유 (通乳), 이뇨 (利尿), 최유 (催乳)작용 등을 하는 것으로 알려져 있다.On the other hand, Donggyu is a seed of Malva verticillata Linne belonging to the family Malvaceae. Mallow is a plant about 60-90 cm in height that grows in a wet field. The stem of Mallow stands upright and has long females (star hair). The leaves are alternate and round, shallowly divided into 5-7 branches, with blunt teeth on the edges. Flowers bloom pale pink in June-July, gathered on leaf axils, and use light plants as traditional vegetables as national streets. Seeds are used as oriental medicine (冬葵子) or gyuja in herbal medicine to be used as a secretion or excretion smooth medicine. Donggyuja is known to act as a bowel movement, pain relief, diuresis, and lactation.
이에 본 발명자들은 에스트로젠 대체 치료에 사용될 수 있는 천연물을 찾고자 예의 노력한 결과, 동규자 추출물이 인간 에스트로젠 수용체에 대한 결합활성을 나타내는 에스트로젠 유사물질로서 폐경기 여성의 호르몬 대체 치료에 효과적으로사용될 수 있음을 밝힘으로써 본 발명을 완성하였다.Accordingly, the present inventors have made efforts to find a natural product that can be used for estrogen replacement therapy. As a result, the present inventors have found that Donggyuja extract can be effectively used for hormone replacement therapy in postmenopausal women as an estrogen-like substance showing binding activity to human estrogen receptor. Was completed.
본 발명의 목적은 안드로젠 또는 에스트로젠과 같은 호르몬의 유사물질로서 천연 추출물을 유효성분으로 함유하는 호르몬 대체 치료용 조성물로 사용될 수 있는 천연 추출물을 제공하는 것이다.It is an object of the present invention to provide a natural extract that can be used as a hormone replacement therapeutic composition containing a natural extract as an active ingredient as an analog of a hormone such as androgen or estrogen.
도 1은 인간 에스트로젠 수용체를 발현하는 재조합 효모를 이용하여 동규자 추출물의 에스트로젠 생성능 (estrogenicity)을 조사한 결과이다. 1 is a result of examining the estrogen generating ability (estrogenicity) of sperm extract using recombinant yeast expressing human estrogen receptor.
C; 무처리군 E2; 17β-에스트라디올C; No treatment group E2; 17β-estradiol
1-1; 동규자 추출물 100 ㎍/㎖ 1-2; 동규자 추출물 1 ㎎/㎖1-1; 100 μg / ml 1-2 of sperm extract; Dongjak Extract 1mg / ml
상기 목적을 달성하기 위하여, 본 발명은 에스트로젠 수용체에 결합활성을 나타내는 에스트로젠 유사물질을 생성하는 동규자 추출물을 유효성분으로 하는 호르몬 대체 치료용 약학적 조성물을 제공한다.In order to achieve the above object, the present invention provides a pharmaceutical composition for hormone replacement therapy comprising the sperm extract to produce an estrogen-like substance showing binding activity to the estrogen receptor.
또한, 본 발명은 에스트로젠 수용체에 결합활성을 나타내는 에스트로젠 유사물질을 생성하는 동규자 추출물을 유효성분으로 하는 호르몬 대체 치료용 건강식품 조성물을 제공한다.In another aspect, the present invention provides a health food composition for treating hormone replacement using an sperm extract that produces an estrogen-like substance showing binding activity to the estrogen receptor.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 에스트로젠 수용체에 결합활성을 나타내는 에스트로젠 유사물질을 생성하는 동규자 추출물을 유효성분으로 하는 호르몬 대체 치료용 약학적 조성물을 제공한다.The present invention provides a pharmaceutical composition for hormone replacement therapy using an sperm extract which produces an estrogen-like substance showing binding activity to an estrogen receptor as an active ingredient.
본 발명의 약학적 조성물에 유효성분으로 함유되는 동규자 추출물은 동규자로부터 물 또는 저급알콜을 이용하여 통상의 방법으로 추출하여 얻을 수 있다.Dongjak extract contained as an active ingredient in the pharmaceutical composition of the present invention can be obtained by extracting from a conventional method using water or lower alcohol.
예를 들어, 열수 추출방법은 동규자를 건조시키고 분쇄하여 중량비로 1 내지 20배의 물을 가한 후 60 내지 100℃에서 1 ∼ 6시간 정도 추출하여 여과 또는 원심분리하고 상등액을 감압농축하여 동규자의 추출물을 제조한다For example, the hot water extraction method is dried and pulverized copper gyuja 1 to 20 times of water by weight ratio, and then extracted for 1 to 6 hours at 60 to 100 ℃ filtration or centrifugation and the supernatant concentrated under reduced pressure to extract the copper gyuja Manufactures
또한, 저급 알콜 추출방법은 동규자에 5 내지 20배의 저급 알콜을 가하고 60 내지 100℃로 가열하면서 1 내지 6시간 동안 환류하고 냉각 및 여과한 후 회전증발기를 이용하여 감압농축하여 동규자 추출물을 얻으며, 이때 여과 후 남은 잔사에 대하여 여과 과정을 2회 이상 반복하여 실시할 수 있다. 이때, 저급 알콜로는 메탄올 또는 메탄올 수용액, 에탄올 또는 에탄올 수용액, 노말프로판올, 이소-프로판올, 노말 부탄올 및 이들의 혼합물을 사용할 수 있으며, 60 내지 80%의 에탄올이 가장 바람직하다.In addition, the lower alcohol extraction method is added to 5 to 20 times lower alcohol to copper ruler, refluxed for 1 to 6 hours while heating to 60 to 100 ℃, cooled and filtered and concentrated under reduced pressure using a rotary evaporator to obtain a copper ruler extract, In this case, the filtration process may be repeated two or more times with respect to the residue remaining after filtration. In this case, as the lower alcohol, methanol or methanol aqueous solution, ethanol or ethanol aqueous solution, normal propanol, iso-propanol, normal butanol and mixtures thereof may be used, and ethanol of 60 to 80% is most preferred.
상기 추출방법에 의해 동규자로부터 추출된 에탄올 추출물이 호르몬 활성 (hormonal activity)을 나타내는지 조사하기 위하여, 인간 에스트로젠 수용체 (human estrogen receptor)를 발현하는 재조합 효모 (recombinant yeast)에 상기 동규자의 에탄올 추출물을 적용하여 반응 여부를 측정하였다.In order to investigate whether the ethanol extract extracted from the sperm by the extraction method shows hormonal activity, the ethanol extract of the sperm is applied to a recombinant yeast expressing a human estrogen receptor. The reaction was measured.
시험물질을 1 ㎎/㎖과 100 ㎍/㎖로 처리한 결과, 양성 대조군으로 사용된 17β-에스트라디올 (17β-estradiol, E2)과 비교할 때 유의적인 차이를 나타내었는데, 양성 대조군인 E2에 비하여 동규자 추출물이 적용된 효모에서 높은 에스트로젠 생성능 (estrogenicity)이 관찰되었다.Treatment of the test substance with 1 mg / ml and 100 μg / ml showed a significant difference compared to 17β-estradiol (E2), which was used as a positive control. High estrogenicity was observed in yeast to which the extract was applied.
상기 실험 결과를 통하여, 본 발명의 동규자 에탄올 추출물이 에스트로젠 수용체에 결합하여 인간 에스트로젠 호르몬의 유사물질로 작용할 수 있음을 확인하였다.Through the above experimental results, it was confirmed that the sperm ethanol extract of the present invention can bind to the estrogen receptor and act as an analogue of the human estrogen hormone.
이러한 효과를 나타내는 본 발명의 동규자 추출물을 유효성분으로 하는 약학적 조성물을 투여함으로써 에스트로젠 투여와 동일한 효과를 기대할 수 있으므로 본 발명의 약학적 조성물은 골다공증의 예방 및 치료제로서 유용하게 사용될 수 있다.Since the same effect as the administration of estrogen can be expected by administering a pharmaceutical composition comprising the sperm extract of the present invention exhibiting such an effect, the pharmaceutical composition of the present invention can be usefully used as a preventive and therapeutic agent for osteoporosis.
본 발명의 약학적 조성물은 임상 투여시에 경구 또는 비경구로 투여가 가능하며 일반적인 의약품 대체 치료의 형태로 사용될 수 있다.The pharmaceutical composition of the present invention can be administered orally or parenterally during clinical administration and can be used in the form of general drug replacement therapy.
즉, 상기 약학적 조성물은 실제 임상 투여시에 경구 및 비경구의 여러 가지 제형으로 투여될 수 있는데, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 경구투여를 위한 고형??에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 동규자 추출물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트 (Calcium carbonate), 수크로스 (Sucrose) 또는 락토오스 (Lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조대체 치료, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌글리콜 (Propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔 (witepsol), 마크로골, 트윈 (tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용 될 수 있다.That is, the pharmaceutical composition may be administered in various oral and parenteral dosage forms in actual clinical administration, and when formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, etc., which are commonly used Is prepared using. Solids for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations include at least one excipient such as starch, calcium carbonate and sucrose in the extract. (Sucrose) or lactose (Lactose), gelatin, etc. are mixed and prepared. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized replacement treatments, suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As a suppository base, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명의 약학적 조성물은 경구, 경피, 피하, 정맥 또는 근육을 포함한 여러 경로를 통해 투여될 수 있다.The pharmaceutical compositions of the invention can be administered via several routes including oral, transdermal, subcutaneous, intravenous or intramuscular.
본 발명의 동규자 추출물의 통상적인 1일 투여량은 0.001 내지 100 ㎎/㎏ 체중의 범위이고, 1회 또는 수회로 나누어 투여할 수 있다. 그러나, 활성 성분의 실제 투여량은 투여 경로, 환자의 연령, 성별 및 체중, 및 환자의 중증도 등의 여러 관련 인자에 비추어 결정되어야 하는 것으로 이해되어야 하며, 따라서 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.Typical daily dosages of the sperm extract of the present invention range from 0.001 to 100 mg / kg body weight, and may be administered once or in divided doses. However, it is to be understood that the actual dosage of the active ingredient should be determined in light of several relevant factors such as the route of administration, the age, sex and weight of the patient, and the severity of the patient, and therefore the dosage may be determined in any aspect of the invention. It does not limit the scope.
또한, 본 발명은 에스트로젠 수용체에 결합활성을 나타내는 에스트로젠 유사물질을 생성하는 동규자 추출물을 유효성분으로 하는 호르몬 대체 치료용 건강식품 조성물을 제공한다.In another aspect, the present invention provides a health food composition for treating hormone replacement using an sperm extract that produces an estrogen-like substance showing binding activity to the estrogen receptor.
본 발명의 동규자 추출물을 함유한 건강식품 조성물을 섭취함으로써 에스트로젠 투여와 동일한 효과를 기대할 수 있으므로 본 발명의 건강식품 조성물은 골다공증의 예방 및 치료제로서 유용하게 사용될 수 있다. 호르몬 유사물질로서 작용하기 위하여, 본 발명의 동규자 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강보조식품류 등이 있다.The health food composition of the present invention can be usefully used as a prophylactic and therapeutic agent for osteoporosis because the same effect as the administration of estrogen can be expected by ingesting the health food composition containing the extract of the present invention. In order to act as a hormone-like substance, foods to which the sperm extract of the present invention can be added include, for example, various foods, beverages, gums, teas, vitamin complexes, and health supplements.
본 발명의 동규자 추출물을 식품 제조시 원료 물질에 첨가하거나 조리된 식품에 적절히 혼합하여 식품을 제조할 수 있으며, 이 경우 최종적으로 제조된 식품또는 음료 중에 동규자 추출물의 함량은 0.1 내지 50 중량% 범위이다.Foods may be prepared by adding the sperm extract of the present invention to a raw material during food preparation or by appropriately mixing the cooked food. In this case, the content of sperm extract in the finally prepared food or drink ranges from 0.1 to 50% by weight. .
이하, 본 발명을 실시예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail by way of examples.
단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.However, the following examples are merely to illustrate the invention, but the content of the present invention is not limited to the following examples.
<참조예 1> 재조합 효모Reference Example 1 Recombinant Yeast
본 발명의 동규자 추출물의 호르몬 활성을 조사하기 위해 사용된 싸카로마이쎄스 세레비지에 (Saccharomyces cerevisiae) ER+ LYS 8127(YER) (미국 Duck university [Chemical Industry Institute of Toxicology, USA]의 Donald C. McDonnell 박사에게 공여 받음)는 CUP1 메탈로싸이오닌 프로모터 (metallothionine promoter)에 의해 발현이 조절되는 hER, hAR 유전자와 리포터 시스템 (reporter system)으로 에스트로젠 반응 요소 (estrogen response element), β-gal 유전자를 안정적으로 발현하는 벡터를 포함하는 재조합 효모이다. 싸카로마이쎄스 세레비지에 ER+ LYS 8217은 3.35 g/㎖ 효모 질소 염기 (yeast nitrogen base, Difco사, USA), 2% 덱스트로즈 (dextrose, Gibco사, USA), 30 ㎍/㎖ L-라이신 -HCl (L-lysine-HCl, Sigma사, USA), 35 ㎍/㎖ L-히스티딘-HCl (L-histidine-HCl, Gibco사, USA)를 포함하는 성장용 배지 (growth media)에 배양하여 유지하였다. 동규자 추출물을 이용한 호르몬 활성 실험에 사용되기 전까지 재조합 효모는 상기 성장용 배지에 20% 글리세롤 (glycerol, Sigma사, USA)을 첨가하여 -80℃ 이하에서 보존하였다.Dr. Donald C. McDonnell of Saccharomyces cerevisiae ER + LYS 8127 (YER) (Duck University [Chemical Industry Institute of Toxicology, USA]) used to investigate the hormonal activity of the sperm extract of the present invention. Donor) is a hER, hAR gene and reporter system whose expression is regulated by the CUP1 metallothionine promoter, which stably expresses the estrogen response element and β-gal gene. It is a recombinant yeast containing a vector. ER + LYS 8217 is a saccharomyces cerevisiae 3.35 g / ml yeast nitrogen base (yeast nitrogen base, Difco, USA), 2% dextrose (dextrose, Gibco, USA), 30 μg / ml L-lysine Incubated in growth media containing -HCl (L-lysine-HCl, Sigma, USA), 35 μg / ml L-histidine-HCl (L-histidine-HCl, Gibco, USA) It was. Recombinant yeast was stored at −80 ° C. or lower by adding 20% glycerol (glycerol, Sigma, USA) to the growth medium until it was used for hormonal activity experiments using sperm extract.
<실시예 1> 동규자 추출물의 제조Example 1 Preparation of Donggyuja Extract
동규자를 100 g 당 2 ℓ의 70% 에탄올을 가하고 90℃로 가열하면서 3시간 동안 환류하고 냉각 및 여과한 후 회전증발기를 이용하여 감압농축하여 동규자 에탄올 추출물을 얻었다.2 L of 70% ethanol per 100 g was added thereto, refluxed for 3 hours while heating to 90 ° C, cooled and filtered, and concentrated under reduced pressure using a rotary evaporator to obtain a copper ethanol extract.
<실시예 2> 동규자 추출물의 호르몬 활성 (Estrogenicity) 측정Example 2 Determination of Hormone Activity (Estrogenicity) of Donggyuja Extract
상기 실시예 1로부터 분리·정제된 동규자의 에탄올 추출물이 호르몬 활성을 나타내는지 확인하기 위하여, 인간 에스트로젠 수용체를 발현하는 재조합 효모 싸카로마이쎄스 세레비지에 ER+ LYS 8127(YER)에 상기 동규자 추출물을 적용하여 에스트로젠 생성능을 조사하였다.In order to confirm that the ethanol extract of the sperm isolated and purified from Example 1 exhibited hormonal activity, the sperm extract was applied to ER + LYS 8127 (YER) in a recombinant yeast Saccharomyces cerevisiae expressing a human estrogen receptor. The estrogen production ability was investigated.
구체적으로, 상기 참조예 1에 따라 -80℃에 보관 중이던 재조합 효모를 용해시킨 후 동일한 성장용 배지에 넣고 진탕 배양기 (shaking incubator)에서 30℃, 300 rpm의 조건으로 증식시켰다. 증식된 재조합 효모를 적정 농도로 희석하고 500 μM의 CuSO4(Sigma사, USA)를 첨가한 후 50 ㎖ 코니칼 튜브 (cornical tube)에 적정량을 분주하였다. 상기 튜브에 실험군으로 본 발명의 동규자 추출물을 각각 1 ㎎/㎖과 100 ㎍/㎖로 처리하고, 양성 대조군으로 17β-에스트라디올 (E2, 10-9M)을 처리하였으며, 용매 대조군으로 100% 에탄올 (absolute ethanol)을 사용하였다.Specifically, the recombinant yeast stored at −80 ° C. according to Reference Example 1 was dissolved, and then placed in the same growth medium, and then grown at 30 ° C. and 300 rpm in a shaking incubator. Proliferated recombinant yeast was diluted to the appropriate concentration, 500 μM of CuSO 4 (Sigma, USA) was added and the appropriate amount was dispensed into 50 ml cornical tubes. The tube was treated with 1 mg / ml and 100 μg / ml, respectively, as an experimental group, and treated with 17β-estradiol (E2, 10-9 M) as a positive control, and 100% ethanol as a solvent control. (absolute ethanol) was used.
각각의 물질이 처리된 상기 실험군 및 대조군을 진탕 배양기에서 30℃, 300 rpm의 조건으로 18시간 동안 배양한 후 각 튜브의 배양액을 동일한 농도로 희석하고 96 웰 마이크로타이터 플레이트 (96 well microtiter plate, Costar사, USA)에 각 군마다 100 ㎕씩을 3웰에 분주하였다. 상기 웰에 2 ㎎/㎖ o-니트로페닐-β-D -갈락토피라노사이드 (o-nitrophenyl-β-D-galactopyranoside, Sigma사, USA), 0.1% 라우릴 설페이트 (lauryl sulfate, Sigma사, USA), 50 mM β-머캅토메탄올 (β-mercaptoethanol, BDH chemical사, England), 200 U/㎖ 옥살리티카아제 (oxalyticase, Enzogenetics사, USA)를 포함하는 Z 완충용액을 분주하고 혼합한 후 20분이 경과된 뒤 발색정도를 마이크로플레이트 판독기 (microplate reader)를 이용하여 420 nm의 파장에서 측정하였다.The experimental group and the control group treated with the respective materials were incubated for 18 hours at 30 ° C. and 300 rpm in a shake incubator, and then the culture solution of each tube was diluted to the same concentration and a 96 well microtiter plate (96 well microtiter plate, Costar, USA) was dispensed into three wells of 100 μl in each group. 2 mg / ml o-nitrophenyl-β-D-galactopyranoside (o-nitrophenyl-β-D-galactopyranoside, Sigma, USA), 0.1% lauryl sulfate (Sigma, USA), 50 mM β-mercaptoethanol (β-mercaptoethanol, BDH chemical, England), and 200 U / mL Z buffer solution (oxalyticase, Enzogenetics, USA) were dispensed and mixed After 20 minutes, the color development was measured at a wavelength of 420 nm using a microplate reader.
그 결과, 본 발명의 동규자 추출물을 각각 1 ㎎/㎖, 100 ㎍/㎖ 농도로 처리한 실험군에서 17β-에스트라디올 (E2)이 처리된 양성 대조군에 비하여 유의적인 차이를 나타내었다. 10-9M의 17β-에스트라디올 (E2)이 처리된 양성 대조군은 약 2.7 정도의 흡광도를 나타낸 반면, 동규자 추출물이 100 ㎍/㎖ 및 1 ㎎/㎖ 처리된 실험군은 각각 2.2 및 3.7의 흡광도를 나타내어 기존에 호르몬 대체 치료에 사용되고 있는 17β-에스트라디올 보다 비교적 높은 에스트로젠 생성능을 나타내었다.As a result, the experimental group treated with Dongjak extract of the present invention at concentrations of 1 mg / ml and 100 µg / ml, respectively, showed a significant difference compared to the positive control treated with 17β-estradiol (E2). The positive control group treated with 10 −9 M of 17β-estradiol (E2) showed an absorbance of about 2.7, whereas the experimental group treated with 100 μg / ml and 1 mg / ml of the copper sperm extract had absorbances of 2.2 and 3.7, respectively. It showed relatively higher estrogen-generating ability than 17β-estradiol, which is conventionally used for hormone replacement therapy.
따라서, 본 발명의 동규자 추출물은 에스트로젠 수용체 결합활성을 나타내는 에스트로젠 유사물질로서 이를 포함하는 조성물은 골다공증과 같은 질병의 호르몬 대체 치료에 유용하게 사용될 수 있다.Therefore, the sperm extract of the present invention is an estrogen-like substance showing estrogen receptor binding activity, the composition comprising the same can be usefully used for the hormone replacement treatment of diseases such as osteoporosis.
상기에서 살펴본 바와 같이, 본 발명의 동규자 추출물은 에스트로젠 수용체에 결합하는 에스트로젠 유사물질을 생성하므로 폐경기 여성의 호르몬 대체 치료를 위한 약학적 조성물로 유용하게 사용될 수 있다.As described above, the sperm extract of the present invention generates an estrogen-like substance that binds to the estrogen receptor, and thus may be useful as a pharmaceutical composition for treating hormone replacement in postmenopausal women.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020010024276A KR20020084876A (en) | 2001-05-04 | 2001-05-04 | Composition comprising an extract of malva verticillata l. for hormone replacement theraphy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020010024276A KR20020084876A (en) | 2001-05-04 | 2001-05-04 | Composition comprising an extract of malva verticillata l. for hormone replacement theraphy |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20020084876A true KR20020084876A (en) | 2002-11-13 |
Family
ID=27703676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020010024276A KR20020084876A (en) | 2001-05-04 | 2001-05-04 | Composition comprising an extract of malva verticillata l. for hormone replacement theraphy |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20020084876A (en) |
-
2001
- 2001-05-04 KR KR1020010024276A patent/KR20020084876A/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20110004603A (en) | Extracts from sophora japonica l. for treating or preventing menopausal complaints, skin-aging, or skin wrinkle | |
US10675316B2 (en) | Composition for preventing and treating climacteric disorder containing extracts of Dendropanax morbifera LEV. as active ingredient | |
KR20210133171A (en) | Pharmaceutical composition for the prevention or treatment of obesity or metabolic syndrome induced from obesity containing evening primrose extract as an active ingredient | |
US20230390352A1 (en) | Composition comprising salvia miltiorrhiza extract as active ingredient for prevention and treatment of depression in menopausal women | |
KR20020084877A (en) | Composition comprising an extract of astragalus membranaceus for hormone replacement theraphy | |
KR102080410B1 (en) | Composition for Preventing, Treating or Improving of Andropause Syndrome Comprising Elderberry Extracts | |
KR101193540B1 (en) | Composition comprising the extract of Astragalus membranaceus BGE.,Cinnamomum cassia and Phellodendron amurensis for preventing and treating of osteoporesis and bone disease | |
KR100934022B1 (en) | Composition comprising an active ingredient isolated from Bogolgol extract or Bogolgol extract excellent in estrogen activity | |
KR102075836B1 (en) | Composition for preventing or treating menopausal syndrome of women comprising Aristotelia chilensis extract, Angelica sinensis extract and Passiflora incarnata extract as an active ingredient | |
KR20020084871A (en) | Composition comprising an extract of cassia obtusifolia for hormone replacement theraphy | |
KR102371112B1 (en) | Anti-oxidant and Anti-obesity composition comprising Complex the extract of Allium senescens.L and crisium setidens as the effient composition | |
KR20020084876A (en) | Composition comprising an extract of malva verticillata l. for hormone replacement theraphy | |
KR20040082951A (en) | Phytoestrogenic composition comprising an extract of chinese licorice root or isoliquiritin | |
JP7312907B2 (en) | Composition for ameliorating symptoms of premenstrual syndrome containing extract of Korean cypress | |
KR100637358B1 (en) | Composition comprising the extract of Glycyrrhizae radix for preventing the toxicity of Endocrine Disruptors | |
KR101293835B1 (en) | Composition comprising the combined extract of Astragalus membranaceus Bunge and Plantago asiatica for preventing and treating obesity | |
KR102068198B1 (en) | Composition containing the extracts or fractions of Circaea mollis Slebold and Zucc for the prevention and treatment of postmenopausal syndrome | |
KR20020084875A (en) | Composition comprising an extract of dyospyros kaki leaves for hormone replacement theraphy | |
KR20020084872A (en) | Composition comprising an extract of alpinia katsumadai for hormone replacement theraphy | |
KR100722303B1 (en) | Promotor of release of Luteinizing hormone comprising Anemarrhena asphodeloides extract or Timosaponin A-III | |
KR20200071380A (en) | Composition for improving premenstrual syndrome symptom comprising extract of Aucklandiae radix | |
US20070020346A1 (en) | Botanical anticancer formulations | |
KR20020084873A (en) | Composition comprising an extract of eugenia caryophyllata for hormone replacement theraphy | |
KR102427768B1 (en) | Composition containing the extracts or fractions of Agastache rugosa for the prevention and treatment of postmenopausal syndrome | |
KR100702184B1 (en) | Promotor of release of Luteinizing hormone comprising Anemarrhena asphodeloides extract or Timosaponin A-III |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |